PharmQuestions: Flashcards
A 67 y/o woman who is a 5-year survivor of breast cancer has completed her treatment regimen with tamoxifen. Current recommendations are that she now undergo an additional period of treatment with:
Anastrazole (aromatase inhibitor)
A 55 y/o woman with breast cancer is about to begin treatment with tamoxifen [Nolvadex]. Which of the following effects should her physican appropriately counsel her about?
Thromboembolic disease
Which of the following adverse effects would be more likely to occur in patients taking exemestane [Aromasin] than in those taking raloxifene [Evista]?
Joint stiffness
Betty, a 61 y/o woman with a triple negative breast cancer that has a high recurrence score is to undergo adjuvant chemotherapy using the AC-T protocol (cyclophosphamide, doxorubicin, taxol). For which of these drugs should the physician pay particular attention to cardiovascular function?
Doxorubicin
Several other drugs used in the treatment of breast cancer also carry particular risks of cardiotoxicity. For which of the following would regular echocardiography be appropriate?
Trastuzumab [Herceptin]
Upon initial drug use, which of the following increases pain arising from bone metastases of breast cancer?
Goserelin [Zoladex]
Corneal changes, visual impairment and cataracts are most likely to occur in women receiving treatment with:
Tamoxifen
Which of the following prevents hetero-dimerization of EGFR receptors and subsequent activation of proliferative signaling?
Pertuzumab [Perjeta]
Patients with BRCA1 & 2 mutations are at increased risk of breast and ovarian cancer. Which of the following statements correctly describes this clinical condition and its management?
Tamoxifen is more effective for BRCA2 tumors than for BRCA1 tumors
Inhibition of CYP19A1 is most appropriately effected by the administration of:
Letrozole ]Femara]
A new patient arrives at the breast cancer clinic clutching her CYP2D6 profile from DNAdirect, intent on having a discussion with her oncologist regarding one of the drugs she may be about to receive as part of her adjuvant therapy for +++ breast cancer. For which of the following drugs has a discussion centered around such a concern?
Tamoxifen [Nolvadex]
A 23 y/o woman with triple-positive (+++) breast cancer is receiving adjuvant chemotherapy following surgical excision of the primary node-negative tumor. Which of the following drugs would not be appropriate as part of her clinical care?
Anastrozole
